IBC
From 6K to holographic projection and from esports to the FIFA World Cup, this year’s 10 IBC Innovation Awards finalists show a clear trend towards global co-operation and remarkable advances in bringing new engagement to content.
Representing the very best of technical excellence in pursuit of real benefits for producers and viewers alike, the Innovation Awards judges were “astounded by the range of imaginative projects submitted and had some really tough decisions to make,” said Michael Lumley, Chair of the international judging panel.
“Although we never look for a theme in our list of finalists, the shortlist usually reflects the wider industry,” Lumley added. “This year you can definitely see that there are a number of projects which are global in their scale and which use new opportunities in connectivity to bring us astounding images, whether that is capturing life under the sea or the excitement of sports.”
The calibre of this year’s shortlist demonstrates that the IBC Innovation Awards are the leading recognition for the application of cutting-edge technology in media and entertainment. The Innovation Awards are unique in that they do not go to new products, but instead to innovative uses of technology, bringing new creative, operational or commercial opportunities to users.
There are three categories: the first, Content Creation , recognises excellence in creating content. The four finalists for this category are:
- Fox Sports for its augmented reality studio for Nascar
- Riot Games for its remote production in Los Angeles of the League of Legends World Championships in Seoul
- SailGP and Timeline Television , again for remote production, this time of SailGP, a new annual, global sports championship re-defining the sport of sailing
- Vodafone in Romania for enabling an 11-year-old guitarist to join a rock band on stage, through a 5G remote link and holographic projection
For the Content Distribution category , the finalists are:
- Associated Press , for its technical audacity in using lasers through open water to bring broadcast quality video from depths of 200m off the Seychelles
- BT Sport for its practical demonstration of the use of 5G for remote production
- COPA90 for its radical new approach to social media and fan engagement globally, from the FIFA World Cup in 2018
The shortlist for the Content Everywhere category is:
- Deutsche Telekom for advancing immersive video experiences with a 6k resolution 360˚ service
- ETV Bharat in India for building a news production and playout platform at a remarkable scale for 24 OTT channels in 13 languages, served by 5,000 journalists
- Mediapro for delivering matches and fan entertainment from LaLiga Spanish football, on Facebook Watch in Indian Subcontinent
Anil Wanvari, Founder, CEO and editor-in-chief of indiantelevision.com, joined the judging panel in London this year, travelling from Mumbai. He commented: “The chance to sit with a group from America, the Middle East and Europe to discuss, debate and explore this extensive list of entries was very exciting.”
“What struck me most, as a first-time judge, is that the entries come from all around the world, each bringing its own unique take on how to engage with audiences today,” he continued. “Agreeing a shortlist of just 10 was really difficult. There were some ground-breaking projects which have achieved great things but did not quite make it in a remarkable year for this competition.”
While the shortlist is announced today, the identity of the winners remains a closely guarded secret until the IBC2019 Awards Ceremony, held at 18:30 on Sunday 15 September . This year IBC is introducing two new awards: the Young Pioneer Award, recognising rising talent in our industry, and the Social Impact Award, recognising those making a positive impact in the wider world. The winners of all these awards and IBC’s highest accolade, the International Honour for Excellence, will be announced at the IBC Awards Ceremony.
Entry to the IBC Awards Ceremony is included in your free IBC exhibition visitor pass. Register now: show.ibc.org/register .
## ENDS ##
Notes to Editors:
About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
IBC2019 Dates
Conference: 13 - 17 September 2019
Exhibition: 13 - 17 September 2019
For more information about IBC2019 visit: show.ibc.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20190704005058/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom